Enovis Co. (NYSE:ENOV) Receives Average Rating of “Buy” from Analysts

Shares of Enovis Co. (NYSE:ENOVGet Free Report) have received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $75.43.

A number of analysts have issued reports on ENOV shares. Stephens began coverage on shares of Enovis in a report on Tuesday, February 13th. They issued an “overweight” rating and a $72.00 price target on the stock. Canaccord Genuity Group lifted their target price on Enovis from $73.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Wells Fargo & Company increased their price target on Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Enovis in a research note on Friday, May 3rd.

Get Our Latest Report on Enovis

Enovis Stock Performance

NYSE:ENOV opened at $47.48 on Wednesday. The stock has a 50-day moving average price of $54.71 and a 200 day moving average price of $56.39. The stock has a market capitalization of $2.60 billion, a P/E ratio of -31.65 and a beta of 1.94. Enovis has a 12-month low of $43.04 and a 12-month high of $66.14. The company has a current ratio of 2.10, a quick ratio of 1.03 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOVGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.50. Enovis had a negative net margin of 4.51% and a positive return on equity of 3.98%. The business had revenue of $516.00 million during the quarter, compared to analyst estimates of $505.62 million. During the same period last year, the firm posted $0.44 EPS. The company’s revenue was up 27.0% on a year-over-year basis. Equities research analysts forecast that Enovis will post 2.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Enovis

Several large investors have recently added to or reduced their stakes in ENOV. Fidelis Capital Partners LLC purchased a new position in shares of Enovis in the 1st quarter worth approximately $34,000. Principal Securities Inc. bought a new position in Enovis during the fourth quarter valued at $41,000. Benjamin F. Edwards & Company Inc. raised its stake in shares of Enovis by 97.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock valued at $47,000 after acquiring an additional 417 shares during the period. GAMMA Investing LLC bought a new stake in shares of Enovis in the 4th quarter worth about $53,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Enovis during the 3rd quarter worth about $82,000. 98.45% of the stock is owned by institutional investors.

About Enovis

(Get Free Report

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Featured Stories

Analyst Recommendations for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.